ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Condition(s) studied
Investigational drug(s) / intervention(s)
ELE-101: ELE-101 solution for intravenous infusion
ELE-101 Placebo: ELE-101 placebo matching solution for intravenous infusion
Study summary
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
Eligibility
Primary outcome measure(s)
- Part 1: Percentage of participants with at least one safety event — Baseline up to Day 8
* Safety will be evaluated by the monitoring of adverse events (AEs), vital signs, blood pressure, heart rate, pulse oximetry, electrocardiogram (ECG) evaluations, clinical laboratory assessments, injection site reactions and physical examination findings. * Suicidal ideation and behavior will be evaluated using the Columbia-Suicide Severity Rating Scale (C-SSRS). * Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) will be captured. * Tolerability will be measured using the SDI questionnaires to rate the intensity of the psychedelic experience alongside recordings of anticipated adverse effects such as nausea and headache. - Part 2: Subjective Drug Intensity Ratings — pre-dose and at multiple time-points up to 24 hours post-dose
\- The SDI questionnaire will be used to rate the real-time intensity of the psychedelic experience
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| MAC Clinical Research | Liverpool | United Kingdom | |
| MAC Clinical Research | Manchester | United Kingdom |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05434156 on ClinicalTrials.gov ↗ ← All trials in the UK